PetMed Express stock gains 4.35 percent on Nasdaq. Morgan Stanley holds USD 1.40 target

Published on 10/20/2026 at 19:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MarketBeat estimates earnings on December 18, 2026. PetMed Express stock costs EUR 1.07 on October 20, 2026, up 4.35 percent on Nasdaq.

Analyst rating and earnings date

Morgan Stanley maintained its Sell rating on September 25, 2026.
One analyst's target implies 16.67 percent upside from USD 1.20.
PetMed Express stock costs EUR 1.07 at Lang & Schwarz on October 20, 2026 at 7:02 p.m. CEST.
MarketBeat estimates the next earnings date as December 18, 2026.

PETS, US7163821066, Illustration mit AI erstellt.

PetMed Express stock gained 4.35 percent on Nasdaq on October 20, 2026, while Morgan Stanley maintained its USD 1.40 target and Sell rating dated September 25, 2026, according to Investing.com. The target stands 16.67 percent above the Nasdaq price of USD 1.20 at 1:06 p.m. EDT. The euro quote was EUR 1.07 at Lang & Schwarz on October 20, 2026 at 7:02 p.m. CEST.

What does the target imply?

Morgan Stanley's USD 1.40 target is above the Nasdaq price of USD 1.20, but its Sell rating shows that the target level does not amount to a positive recommendation. Investing.com lists one analyst in its current survey, with zero Buy ratings, zero Hold ratings and one Sell rating dated September 25, 2026.

Stock stays near its yearly low

PetMed Express traded between USD 1.15 and USD 1.20 on October 20, 2026, while its 52-week range was USD 1.15 to USD 4.10 as of October 19, 2026. The market capitalization was USD 26.0 million on October 20, 2026, and the trading volume reached 62,401 shares at 1:06 p.m. EDT.

Revenue pressure sets the backdrop

PetMed Express operates an online pet pharmacy and sells prescription and non-prescription medicines, food and health products for dogs, cats and horses. The investor-relations page identifies the latest quarterly reporting package as fiscal 2027 first quarter material, while MarketBeat lists USD 62.00 million in expected revenue and negative USD 0.11 in expected earnings per share for fiscal 2027 second quarter.

MarketBeat estimates December 18, 2026 as the next PetMed Express earnings date. That date is later than the October 13, 2026 estimate shown for the fiscal 2027 second-quarter report, so the next scheduled update is the more relevant calendar marker.

Peer valuation remains mixed

PetMed Express had a price-to-earnings ratio of negative 0.87 and a market capitalization of USD 26.0 million on October 20, 2026. Chewy traded at USD 21.55, up 4.97 percent, with a price-to-earnings ratio of 32.66 and a market capitalization of USD 8.7 billion; Petco traded at USD 2.35, up 0.43 percent, with a price-to-earnings ratio of 23.51 and a market capitalization of USD 673.0 million.

Analyst target leads the market picture

The key investor comparison is between the USD 1.40 target and the USD 1.20 Nasdaq price, not between the target and the euro quote. PetMed Express was trading at EUR 1.07 at Lang & Schwarz on October 20, 2026 at 7:02 p.m. CEST. The Nasdaq session showed a 4.35 percent gain against the prior close of October 19, 2026, when the stock stood at USD 1.15.

The further course of trading is shown by the continuously updated real-time quote of PetMed Express stock.